| 초록 |
The usage of protein corona shielded nanoparticles (PCSNs) as a nanocarrier is effective targeting drug delivery platform. However, the investigation of the controlled drug release profile of PCSN platform inside the cancer cell is still challenging for the perfection of the drug delivery. Here, the stimuli-responsive and biodegradable mesoporous organosilica nanoparticles (MONs) can be reduced by the GSH from the tumor microenvironment and degraded achieving better release than the conventional mesoporous silica nanoparticles (MSNs). The degradation can occur higher amount of the delivery of the drug, leading to the effective cancer cell death than the MSNs. Not only enhancing the release profiles, but the platform is also expected to achieve universality of the protein modification, with various kinds of the protein-affibody. Depending on the type of protein affibody of the nanoparticle, the cancer cells with certain overexpressed receptors could be targeted respectively. |
